Nanobiotix (NASDAQ:NBTX) Shares Down 4.3% – What’s Next?

Nanobiotix S.A. – Sponsored ADR (NASDAQ:NBTX)’s share price fell 4.3% during mid-day trading on Tuesday. The company traded as low as $32.47 and last traded at $31.8910. 2,874 shares changed hands during mid-day trading, a decline of 97% from the average daily volume of 88,874 shares. The stock had previously closed at $33.31.

Wall Street Analyst Weigh In

A number of equities analysts have weighed in on NBTX shares. Leerink Partners increased their price target on shares of Nanobiotix from $37.00 to $46.00 and gave the stock an “outperform” rating in a research note on Thursday, June 4th. Weiss Ratings restated a “sell (d-)” rating on shares of Nanobiotix in a report on Friday, July 17th. Finally, Guggenheim initiated coverage on Nanobiotix in a research report on Tuesday, September 15th. They issued a “buy” rating and a $64.00 target price on the stock. Four investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $46.67.

Nanobiotix Stock Down 3.2%

The firm’s 50-day moving average price is $38.67 and its 200-day moving average price is $37.30.

About Nanobiotix

Nanobiotix is a clinical-stage biotechnology company focused on developing nanomedicine-based therapies for cancer. The company’s technology is designed to improve the effectiveness of radiotherapy by using nanoparticles that interact with radiation inside tumors, with the goal of enhancing tumor-cell destruction while limiting damage to surrounding healthy tissue.

Its lead product candidate, NBTXR3, is an investigational radioenhancer consisting of functionalized hafnium oxide nanoparticles.